AP@Home is a European research project focused on improving home treatment of patients with diabetes. A variety of academic institutions, clinical research centres and commercial partners from across the world formed the consortium that worked together on this project. The primary aim was to develop an artificial pancreas that determines when and how much insulin should be delivered to a patient, and automatically does so when necessary.
The artificial pancreas consisted of an off the shelf Continuous Glucose Monitor (CGM) to determine blood glucose level, paired with an off the shelf insulin pump to deliver insulin to the patient. Triteq developed the interface between these two devices to allow an algorithm to determine how much, if any, insulin to deliver to the patient to maintain a suitable blood glucose level.
This project required the expertise all of the teams at Triteq, but more heavily involved the hardware and software teams. The first prototype to be developed used wireless communications between a device made by Triteq, the CGM and the insulin pump together with a PC for displaying data. Although not the final solution, this was used for clinical trials in hospitals with successful results.
The second prototype removed the PC from the system so that the artificial pancreas could be used at home with minimal devices. Triteq developed the electronics further to include custom power management and charging, a wireless interface to an Android phone to control the insulin pump, and embedded software to interface to the CGM. This was encased in a custom enclosure that also held the CGM and could attach to the patients clothing ensuring minimum disruption to daily activities.
This prototype was used in clinical trials where patients tested the device at home for 3 months, day and night. This once again had successful results.
The project concluded with significant advances made to the feasibility of this technology. The excellent results from clinical trials give confidence in the prototypes developed by Triteq, and these are expected to form a basis for commercial application of the technology.